Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin vs Moxifloxacin for Mycobacterium xenopi Pulmonary Infection
NCT01298336Phase 3Completed
- Sponsor
- CHU Amiens-Picardie
- Start
- Mar 2011
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of moxifloxacin in Mycobacterium xenopi infection (2 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Sputum conversion at 6 months. Started Mar 2011; status: completed.
02
Drugs
moxifloxacin
03
Conditions
Mycobacterium xenopi infection
Beyond the preview
Go deeper on NCT01298336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01298336.